Milatuzumab: a promising new agent for the treatment of lymphoid malignancies

Author： Mark Tomer   Martin Peter   Leonard John P   Niesvizky Ruben  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.1, 2009-01, pp. : 99-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens

By Poulakou Garyphallia   Giamarellou Helen  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 2, 2008-02 ,pp. : 225-243

Informa Healthcare

Access to resources Recommend Favorite

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

By Winer Eric S   Ingham Randall R   Castillo Jorge J  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 355-361

Informa Healthcare

Access to resources Recommend Favorite

Panobinostat in lymphoid and myeloid malignancies

By Khot Amit   Dickinson Michael   Prince H Miles  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 9, 2013-09 ,pp. : 1211-1223

Informa Healthcare

Access to resources Recommend Favorite

BOND: Cetuximab a promising new agent for colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1396, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?

By  

Current Medicinal Chemistry, Vol. 23, Iss. 22, 2016-07 ,pp. : 2350-2362

Bentham Science Publishers

Access to resources Recommend Favorite